Steve Bryson, PhD, science writer —

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

Nighttime COPD Symptoms Impact Activities, Quality of Life: Survey

Nighttime breathing symptoms related to chronic obstructive pulmonary disease (COPD) significantly impaired daily activities and health-related quality of life, a survey of patients and physicians revealed. Most of the surveyed patients (74%) reported having nocturnal symptoms, while physicians reported that they prescribed treatments based on 24-hour symptom relief for…

Ensifentrine Clinical Trials in China OK’d, Nuance Announces

Nuance Pharma has been given the go-ahead to launch clinical trials in China to evaluate the investigational therapy ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The company asked permission, in the form of an investigational new drug (IND) application, to conduct both Phase 1…

MgIG-Salmeterol Combo Fares Well in Rat Study

Salmeterol, combined with the root extract derivative magnesium isoglycyrrhizinate (MgIG), eased the signs and symptoms of chronic obstructive pulmonary disease (COPD) in rats, a study demonstrated. Salmeterol-MgIG combination therapy was more effective than the approved salmeterol-fluticasone combination in improving lung function and reducing inflammation. The researchers suggested…

Discovery of CMA-1 Enzyme May Lead to New Treatment for COPD

Scientists say the discovery of a triggering enzyme in the lung tissue of people with severe chronic obstructive pulmonary disease (COPD) could lead to a new treatment for the inflammatory disorder. Elevated levels of the newly uncovered enzyme, called chymase-1 or CMA-1, were found in tissue isolated from the lungs…

TSOI Nets IND Number Ahead of Proposed JadiCell Clinical Trial

Note: This story was updated June 6, 2022, to note that the U.S. Food and Drug Administration has assigned an Investigational New Drug application (IND) number to Therapeutic Solutions International experimental JadiCell therapy. The FDA has not yet approved the company’s IND application. The U.S. Food and Drug Administration’s review…

FDA OKs World’s First Infrasound Stethoscope in US

The U.S. Food and Drug Administration (FDA) will allow Sanolla’s VoqX to be used in the clinic, the first stethoscope that can be used to detect infrasounds — acoustic waves that humans cannot hear. The primary care stethoscope — a diagnostic tool clinicians normally use to listen to sounds…

ENA, COPD Foundation Team Up on INNA-051 Antiviral Nasal Spray

ENA Respiratory is developing its first-in-class, broad-spectrum antiviral nasal spray — known as INNA-051 — for populations at risk of developing complications from respiratory viral infections, including COVID-19. Now, the Australian company is teaming up with the COPD Foundation, a nonprofit with a mission to improve the…